Future Outlook of the Peptide And Oligonucleotide CDMO Market: Growth, Trends, and Emerging Opportunities Explored
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Expected Growth Rate of the Peptide And Oligonucleotide CDMO Market Based on Industry Projections?
In recent times, the peptide and oligonucleotide cdmo market has seen significant expansion. Projected growth indicates an increase from $2.16 billion in 2024 to $2.42 billion in 2025, resulting in a compound annual growth rate (CAGR) of 12.1%. Factors contributing to this growth during the historical period include heightened demand for therapeutic agents, developments in synthesis and manufacturing processes, tendencies towards personalized medicine, regulatory norms, and a heightened emphasis on antiviral peptides and mRNA vaccines, showcasing the potential of oligonucleotides for vaccine development.
In the coming years, the peptide and oligonucleotide CDMO market is projected to experience significant expansion. By 2029, the market is predicted to reach a value of $3.79 billion, growing at a compound annual growth rate (CAGR) of 11.9%. This anticipated growth during the forecast period can be credited to the escalating demand for personalized medication, the progress in biotech, widening applications, an upward trend in outsourcing, and the increasing prevalence of chronic ailments. Trends expected to dominate the forecast period consist of personalized treatment methods, advancements in technology, challenges in maintaining quality control, worldwide expansion, and the heightened cooperation among biopharmaceutical enterprises.
Which Major Market Drivers Are Expected to Boost the Peptide And Oligonucleotide CDMO Market’s Growth Potential?
The rise in the uptake of personalized medicine is anticipated to boost the expansion of the peptide and oligonucleotide CDMO markets. Personalized medicine involves the customization of health care, according to each individual’s genetic makeup, surroundings, and lifestyle. This surge in personalized medicine usage comes on the back of several factors, including advancements in genomic technologies, a deeper understanding of disease mechanisms at the cellular level and the increased demand for targeted treatments that suit each patient’s genetic profiles and medical histories. Contract development and manufacturing organizations (CDMOs) focusing on peptide and oligonucleotide play an integral part in personalized medicine by generating bespoke therapeutic peptides and oligonucleotides to meet individual patient requirements. As an example, in February 2024, as per reports from the Personalized Medicine Coalition, a UK organization advocating the implementation of personalized medicine, the Center for Drug Evaluation and Research (CDER) under the Food and Drug Administration (FDA) authorized 16 new personalized treatments for patients with rare diseases, a significant increase from 6 in 2022. Hence, the burgeoning adoption of personalized medicine is fueling the expansion of the peptide and oligonucleotide CDMO sectors.
Get Your Free Sample of the Global Peptide And Oligonucleotide CDMO Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp
What Companies Are At the Forefront of Innovation in the Peptide And Oligonucleotide CDMO Market?
Major companies operating in the peptide and oligonucleotide CDMO market are:
• Thermo Fisher Scientific Inc._x000D_
• Merck KGaA_x000D_
• Ajinomoto Co. Inc._x000D_
• Lonza Group Ag_x000D_
• Wuxi Apptec Co. Ltd._x000D_
How Are Emerging Trends in Consumer Behavior Affecting the Peptide And Oligonucleotide CDMO Market?
Leading businesses in the peptide and oligonucleotide CDMO market are honing in on building strategic alliances as a way to improve their services, broaden their technological abilities, and extend their market presence. Partnerships specifically designed for peptide development and production symbolize cooperative arrangements between two entities targeting to create and manufacture peptide-based treatments. As an instance, in May 2023, PolyPeptide Group AG, a CDMO based in the US, formed a partnership with Numaferm GmbH, a biotech company from Germany, specifically for peptide development and production. The objective of this partnership is to capitalize on PolyPeptide’s cGMP manufacturing abilities and market penetration, as well as Numaferm’s aptitude for sustainable peptide manufacturing and biochemical production platforms. The two companies are committed to collaboratively explore the creation of viable peptide candidates with the intention of achieving a more sustainable production of peptide-based APIs.
Get Instant Access to the Global Peptide And Oligonucleotide CDMO Market Report with Swift Delivery!
What Are the Major Categories and Their Growth Dynamics in the Peptide And Oligonucleotide CDMO Market?
The peptide and oligonucleotide cdmo market covered in this report is segmented –
1) By Product: Peptides, Oligonucleotides
2) By Service Type: Contract Development, Contract Manufacturing,
3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users
Subsegments:
1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services
What Regions Are Propelling Growth in the Peptide And Oligonucleotide CDMO Industry?
North America was the largest region in the peptide and oligonucleotide CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Key Parameters Define the Peptide And Oligonucleotide CDMO Market’s Scope?
A peptide and oligonucleotide CDMO (contract development and manufacturing organization) refers to a company that provides services for the development, manufacturing, and supply of peptides and oligonucleotide-based therapeutics. These organizations offer expertise in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to support the production of peptides and oligonucleotides for various companies.
Browse Through More Similar Reports By The Business Research Company:
Biosimilar Therapeutic Peptides Global Market Report 2024
Glucagon-like Peptide 1 Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report
Cell Penetrating Peptide Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cell-penetrating-peptide-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
